as well as favorable foreign currency impact. Segment income totaled $20 million in the quarter, an increase of 0.6% or down 0.6% on a constant currency basis with segment income margin of 32.4%. Segment income margin improved 438 basis points sequentially and is within our long-term range of low to mid 30s. segment income margin decline versus the prior year quarter, primarily reflecting higher costs. Turning to the balance sheet, cash generation, and capital deployment. In the second quarter, we delivered positive operating cash flow of approximately $88 million. Capital expenditures for the quarter totaled $46 million, supporting Sterigenics capacity expansion projects for future growth, EO facility upgrades, Nordion's Cobalt 60 development initiatives, and the clean room expansion at Nelson Labs. Our balance sheet continues to be well positioned to support our capital allocation priorities. Our net leverage ratio further improved to three times for the second quarter, marking an important milestone as we reached our long-term target leverage range of two to three times and our liquidity remains strong. As Alton noted, we are increasing our 2026 outlook for both revenue and adjusted EBITDA constant currency growth. We now expect total company revenue to grow to a range of $1.236 billion to $1.254 billion, representing 5.25 to 6.75% constant currency growth and an estimated 100 basis point foreign currency benefit. Based on recent exchange rates, we expect foreign currency to be a slight headwind in the third quarter. We expect adjusted EBITDA to grow to a range of $634 to $643 million, representing 5.75% to 7.25% constant currency growth and an estimated 100 basis point foreign currency benefit. Our 2026 outlook assumes total company pricing to be within our long-term 3% to 4% range. For 2026, we continue to expect Sterigenics to deliver mid to high single-digit constant currency revenue growth year-over-year. We expect Nordion to grow constant currency revenue in the low to mid single digits in 2026 with second half revenue split approximately evenly between Q3 and Q4. For Nelson Labs, we continue to expect full year 2026 constant currency revenue growth to be in the low single digits. Consistent with what we have previously communicated, we expect segment income margin in the low to mid 30% range. Moving on to other outlook items. Based on the current forward rate curve and the interest savings we realized from our most recent term loan repricing, we are improving our 2026 interest expense outlook to a range of $135 million to $142 million from our prior range of $135 million to $145 million. We are also improving our effective tax rate applicable to adjusted net income to a range of 27% to 28%. We continue to expect depreciation to increase in 2026 consistent with the increase we experienced in 2025. On a weighted average basis, we expect a fully diluted share count in the range of 289 million to 291 million shares. Taking these factors into account, we are improving our adjusted EPS outlook range to $0.95 to $1.01 per diluted share from our previous range of $0.93 to $1.01. With several key projects progressing as planned and half of the year now behind us, we expect capital expenditures to be in the range of $200 million to $225 million. We expect continued net leverage ratio improvement compared to 2025. Finally, as usual, our outlook does not assume any M&A activity. I'll now turn the call back over to Alton.

Thank you, Jon. We delivered a strong quarter highlighted by solid execution across our businesses and an increase to our full year outlook. These results reflect the essential role we play in supporting healthcare around the world, the strong partnerships we have built with our customers, the resilience of our business, and the commitment of our teams. I'm excited about the opportunities ahead and confident in our ability to execute on our priorities and to create long-term value for our stakeholders. I would also like to thank our associates, customers, and shareholders for their continued support, and I look forward to meeting with many of our investors in the months ahead. At this point, operator, let's open the call for questions.

We will now begin the question and answer session. To ask a question, you may press star, then one on your touchtone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question, Please press star then two. At this time, we will pause momentarily to assemble our roster. The first question is from Sean Dodge with BMO. Please go ahead.

Hey, good morning. This is Chris Charlton on for Sean.

Thanks for taking our questions and welcome. We're just starting on Nelson Labs. It's a strong quarter here. Can you share some more detail on the drivers of the improvement in the quarter? Is this primarily just beginning the last EAS headwinds, or are there any other areas you're seeing strength?

And then how much visibility do you have into this continuing in the back half of the year? Thanks.

Yeah, hey, Chris. Alton here. Thanks for the question. Yeah, we're really pleased. with the second quarter performance of Nelson Labs with the 5.4% constant currency growth. We got some good news from a few customers that were looking to work with Nelson and that positively impacted our results here in Q2. And we continue to feel good about the underlying demand that we see in the marketplace. our role as a trusted partner with our customers. So overall, again, feel really good about the performance in Q2 and how the team really focused on serving their customers. And again, feel good about the environment going forward here in the second half of the year. Okay, great. And then on stereogenics, can you share any more detail on how volumes have been trending across your categories, med tech, and Bioprocessing and Commercial. I know you've previously mentioned bioprocessing being a small but quickly growing component of and then commercial kind of being a more challenging backdrop. Is this still the case or have there been any changes to the dynamics across these categories? Sure. So, yeah, so maybe a couple of comments on Sterigenics. So the 7% constant currency growth in the quarter, again, really pleased with that performance. Volume of 2.7%. Again, we feel really good about that. Just want to bring your attention and others' attention to the fact that we had a pretty tough comparable versus Q2 2025, where we grew 10% last year with a 6% volume contribution there. So again, really, really strong performance from that team. Overall, we see a stable demand environment for our Sterigenics business. We obviously have a really broad spectrum of customers within that business, over 2,000 customers. Overall, we see strong growth across that full portfolio. Your point around bioprocessing, yeah, a smaller part of our business, but we grew well in that business, and we continue to focus on that with our commercial teams. Great. Thanks again. Thanks.

The next question is from Evie Kozlowski with Goldman Sachs. please go ahead.

Hi, thank you for taking my questions and great work with you, Michael, over the last several years and congrats, Alton, on the new role. I think just to start, Alton, maybe walk us through some of your top priorities kind of within the first year as CEO and then any thoughts on kind of driving additional synergies between the businesses or commercial strategy update.

Yeah, absolutely. Hey, Abby, thanks for the question. Really priority one for me here in the short term is to ensure that I understand the business Get to know my team, understand our processes, and really determine our strengths and our areas of improvement. And key to the process of understanding the business is meeting and understanding and assessing our talent. So one of my most important jobs as the CEO is to ensure that we've got top talent in the organization, and this is an area that I've been working to understand. Next is really how we partner with our customers. So I need to understand how we partner with them, how they perceive us, and how we work across Sotera Health to really develop differentiated solutions. And I'll hit a bit here on that cross-business unit or one Sotera offering here in a second. Last thing I'll say before I get into that is I want to build on the customer-focused culture that we have here today. Real compliments to Michael, John, Jason, the rest of our leadership team on building a customer-first culture here. It's a real pleasure to be able to join a company like that, and I'm fortunate to be a part of this. But I want to ensure that every associate at Sotera Health understands how important their role is. and that they operate with a high level of urgency to deliver our solutions and delight our customers every single day. So that is one of my big focuses here is just customer focus. Again, understanding we are a service business and we've got to delight our customers every single day. I think a real opportunity that we have is around our one Sotera offering or across business unit work. There's been a lot of really good work done over time here, but I think there's more opportunity. And the more I get into seeing the differentiated solutions we have, we're at our best when we're working together.

Great. That's super helpful. And then on stereogenic volumes, I know you touched on it a bit, but that came in above our expectations. I guess, what are you guys seeing from a competitive standpoint in that market? And then, you know, versus kind of broader end market trends and maybe talk through some of the competitive wins with new customers and how those are trending.

Sure. So, you know, it's a competitive market. We haven't seen any significant difference in competition here in the last quarter, I think in the first half of the year. overall. So that's the first point. Second, we spent a lot of time with our team as we put our guide together for the second half of the year, and that really informed the confidence that we have in our guide. So we do not see a slowdown in demand in Sterigenics. We recognize there have been some mixed data points out there with some of the providers, but we think in general, The indicators are pretty constructive, and we've seen a lot of med techs out there with really strong numbers here in Q2 and guides as well. So overall, competition, pretty similar. We continue to like our position in the market, and we're confident in our guide based on where we see the business heading.

Awesome. Thank you. The next question is from Luke Sergott with Barclays. Please go ahead.

Great, thanks. I just want to follow up on that. You guys outperformed your other large peer. Dig in a little bit on what differentiates you guys from a mixed perspective. Is it more weighted towards EO where you're catching that's a faster part of the market or more demand coming from those volumes that are going to EO? Sterilization Technologies versus your gamma and x-ray. Just trying to understand there the puts and takes. And if you're not seeing, like you said, the volumes are okay, but we hear plenty of noise on the ACA headwinds potentially hitting the space and coming through. So is that one of the reasons why you feel like you'd be insulated because it's a more strategic part or more necessary aspect of what you guys provide?

Yeah, thanks for the question. I will start with, I'm only a couple months in here, so I may not be able to hit on every single one of those points that you brought up, but I'll give you my perspective. One, you know, can't really comment on competition and what's going on with their business, but I will say I know that we are higher indexed into the U.S. versus outside the U.S. compared to our primary competitor. That's one. but I think high level, again, when we get really deep with our teams, we're just not seeing that slowdown in demand. I think on the technology side, I've been doing everything I can to get out to as many facilities as possible and I've been really impressed with what our teams do. And again, we've been making real progress on this cross business unit work or bringing the full force of Sotera Health into developing solutions for our customers. I'd like to think that we're making a difference there and our customers are noticing, but give me a little bit more time as I get deeper into the role and longer in the seat and I may have a more fulsome answer for you.

All right, great. And then I guess from a margin perspective, particularly around Nelson, you guys talked about The higher costs step up here in the core. Can you dig in there what drove those elevated costs? And then as you're bringing on the clean room expansions and doing that, how do we think about that through the second half or even in the 27 as the capacity and utilization picks up in the new facilities or the new rooms?

Sure. Thanks for the question. So the first thing I'll mention is that We're really happy with the sequential margin increase of 438 basis points from Q1 to Q2 for Nelson Labs. So the team did a really nice job there executing in Q2. Also highlight the fact that we are still guiding our full year margin to load the mid 30s range for Nelson. So we expect to stay within that range. the team's doing again a nice job of responding to customer requests and you know as you as has been noted we perform better than we expected here in Q2 some of that growth was due to additional business that was earned in Q2 and our team really did their best to deliver on that in the quarter and we benefited from that financially you know as we go forward again for the full year. Again, we continue to guide to that low to mid 30% range for margins. Great. Thank you.

The next question is from Ryan Halstead with RBC. Please go ahead.

Good morning. Thanks for taking my questions and welcome to the calls. My first question is on Nelson Labs. Just was interested in any update on the validation testing pipeline and how you see that progressing in the back half of the year and how we should think about kind of the cadence of that impacting versus the guide.

Yeah, thanks for the question, Ryan. Appreciate it. So we feel good about the pipeline. We've got a number of opportunities that we're hopeful will contribute to additional growth to the business. That said, what we know and all the data that we are analyzing for Nelson Labs is what is informing our guide for the balance of the year.

Okay. And then on, you mentioned inflation as a headwind on margins. Be helpful just to hear What are the cost inflation that you're facing? Is it transitory? Are these related to some of the geopolitical events? Just any more color on that would be helpful.

Hey, Ryan. It's John. Thanks for the question on that. We're not seeing anything extraordinary in inflation. It's standard inflation coming through. Labor cost increases. and standard things on materials. Nothing extraordinary. We really don't have any meaningful exposure from a knock-on effect of the Middle East. Some very minor costs in Europe for utilities, things like that, but nothing significant there.

Okay, great. Thanks.

The next question is from Casey Woodring with JP Morgan. Please go ahead.

Thank you for taking my questions and congrats on the new role, Alton.

Looking forward to working with you.

Maybe just the high level one here, looking at the guide, you raised the high end after the beat here. I think last year around this time after you beat, you only raised the low end. So maybe just talk a little bit about the seemingly improved visibility you have here and then moving forward, what's giving you enough confidence to raise at the high end there?

Yeah, Casey, thanks for the question here. Maybe just a quick thought or two on just my philosophy around guidance. The first point I'll make is I'm very aligned with how Michael, John, Jason have handled guidance in the past, and I think you'll expect a similar approach here. Our goal is to provide realistic guidance and to be able to provide information to our investors so they understand how we're thinking about the business and what's going on with the company. So that's the first piece. Second piece, obviously we're really pleased with the performance of the company in Q2 and the first half of the year. And when we raised our guidance, there were a lot of factors we had to take into consideration. And a few of those are that we see a meaningful uptick in growth in sterigenics in the second half of the year compared to the first half. So that's contemplated in our guidance. The other thing that's contemplated is John mentioned in his opening remarks the Nordion business. We guided 40 to 45% of full year revenue to hit in the first half. We actually achieved above the top end of our range. So some of the revenues we were expecting in the second half shifted into the second quarter based on customer requests. So we had to take that into consideration as well. You pull that together, we look at what we see in our markets, we're again close to our customers, looking at our backlogs, etc. That's what informed our 25 basis point increase to both revenue and EBITDA guide here.

Got it. That's helpful. Maybe just if you could spend a minute walking us through just the broader decision to build out the X-ray capacity that you've got coming online over the next couple of years. You've talked about it previously, or at least you guys as a company have. Is that something customers are asking more of these days? Or are you kind of building out that new capacity, anticipating the market might move more towards X-ray capacity? just any thoughts around that and then what would the margin implications be once you guys open these new facilities and more volume goes towards x-ray?

I'll start. Thanks for the question. I'll start and then I'll hand it off to John on some of those because obviously those decisions were made before I joined the organization but a couple things on our new x-ray facility. The good news is things are progressing very well so we're on track. We've got a number of customers in validation but we also have Revenue starting to flow through that facility here starting in Q3. And that's one of the factors why we're comfortable with the uptick in growth from Sterigenics in the second half of the year compared to the first half. So overall, things are going very well in x-ray. I will say that, you know, as a leading sterilization provider, we want to have all modalities, and we want to be able to offer that to our customers. But let me hand it off to John to get into some more specifics here.

Yeah, historically, the big thing around this was, if you look back a few years, our biggest competitors also putting in a number of x-rays. As Alton said, we were looking at the opportunity and making sure we had a complete offering for our customers, and if you Go back in time, we even contemplated doing more than that. So we thought it was at least important to put one in. It was a strategic decision by the board. And it was one where we normally, as you've heard from us before, we target 40% commitments from our customers. And that was one we made a little bit more of a bet on. And I'm happy to report, as Alton mentioned, the pipeline is filling. It's giving us optimism in the back half as we grow here. but again, it's one that we thought was a strategic decision and marker for us to put down to have that complete offering. That said, we are a world leader in Cobalt-60. We believe strongly in gamma sterilization and that continues to be a critical part of our portfolio going forward and X-Ray is more of a compliment as we look at it. On your margin question, the great thing about these facilities. You don't have a lot of incremental fixed costs coming in when you bring in outside the depreciation, bring in these facilities. It's not hugely people intensive or material intensive. The big thing is electricity, so you can turn them on and off. So there's no notable margin impact. We've actually absorbed some costs already over the last 12 months that you wouldn't even see in the financials, really.

Got it. Understood. Thank you, guys.

The next question is from Brendan Diggins with Citi. Please go ahead.

Hey guys, thank you for taking my question and congrats on the quarter. I want to spend a little bit of time on the increased EBITDA guide. Understand that the Nelson Live Guide was kind of maintained in the low to mid 30% range, but I was wondering if you could touch on the Sterigenics and Nordian outlook just given some of the shifts that kind of went on in Nordian and the increased outlook in Sterigenics.

Yeah, sure. I'll start with Sterigenics. So again, we put up a 7% constant currency growth in Q2 after 6.1% in Q1. In the second half of the year, we are expecting an uptick in growth compared to what we saw in the first half. And we've got pretty good confidence around that for a few reasons. One, I talked about overall Demand seeming stable in the marketplace, but also more importantly, when we talk to our customers, look at our backlog, pipeline, et cetera, it gives us confidence in the guide that we provided. In addition, there are a few tailwinds that we're expecting in the second half of 26 compared to the second half of 25. The first is we've got, for our facility shutdown schedules, that is favorable in the back half of the year here in 26 again versus 25. also we've mentioned before a large customer who previously in-sourced their sterilization they're now outsourcing to us we will see that impact in the second half and then also x-ray with our new facility with the additional revenues coming on there all of those contribute to the the guide that we have and again why we've got confidence in this you know pretty meaningful uptick in growth in sterigenics in the second half for Nordion we are expecting again to as we guided previously low to mid single digits growth for the full year and we expect Q3 and Q4 to have similar revenues so you put that all together and that is what informed us to create and provide the guide for the full year that we did.

Great, thank you. And then I was wanting to touch on the increased CapEx budget for this year, just kind of what's behind the increase and does this change at all the outlook for 2027 in terms of stepping down? Thanks again.

Yeah, no, I can kick that off and then we can hand it off to John if we want to get into a little bit more details there. But no, we do see a meaningful step up in CapEx here in 2026. We've got a number of growth investments that are driving that, but as well, We've got the facility enhancements on the EO side that are driving that. We are going to be substantially complete with those facility enhancements by the end of 2026. There's going to be a little bit of work in 27 and a little bit of capital that will bleed into 27. But overall, those are the key drivers for 26.

Yeah, and for 27, Brendan, we continue to expect a meaningful step down from 26 to 27 in CapEx spending. and overall, just as we think about our three-year commitment that we had back in investor day, we're very much on track to deliver the free cash flow commitment that we had of $500 to $600 million.

Appreciate it. Thank you.

The next question is from Dave Windley with Jefferies. Please go ahead.

Hi, thanks. I had a few, some clarification if I could. You've called out, kind of emphasized the positive impact in Nelson in 2Q and hammering home on the low 30s margin. Should I interpret that these projects that you're referring to are clients that came in in 2Q, that those were, I'll call more transient projects? Yes. in the quarter, or were these clients that you're onboarding for more ongoing work? And was that activity in 2Q part of the enhancement of margins sequentially?

David, thanks for the question. I appreciate that. So the short answer is it's both for Nelson. So when you look at Q2, we did, and you're aware, we outperformed our guide there, and that was because We did earn business within that quarter. Some of that business is going to be completed in that quarter, but some of that business is also going to continue throughout the year. Part of how our business works is if we get a project, we have an opportunity to win more business in the future as well. So that's a key part of the Nelson story, and historically they've done a nice job of that. I think that addresses the Nelson component there.

Yeah, the only thing I would add is just on your sequential margin question, the step up in revenue of which that was a contributor really drove it. We've gotten great contribution margins that come with the business. So the step up in revenue is really what helped drive the margin improvement sequentially, David.

Got it. Great. Thanks. So I was just refreshing my memory. The other topic I had here is around pricing and I'm thinking about this more broadly. I think longer term history, you talked about three and a half to five. I think maybe toward the end of last year, you'd revise that to three to four. You're still in that three to four range. I think one of the efforts or opportunities that you thought you had was pricing, I'll call it pricing the value on the enhancements to EO and getting appropriately paid for that higher level of quality. Where does that stand? And is that, I presume it's baked into the three to four, but how should I think about your progress against that?

Yeah, thanks for the question there. So obviously we saw some strong pricing from Sterigenics in the quarter and in previous quarters as well. And I've I view that as customers recognizing the value that we provide, but it's also a nice job by our commercial team securing those price increases. We expect similar type of pricing from Sterigenics here within the year, and we do expect the total company improvement of pricing to be consistent with the guide that we provided of three to four percent. We are making progress on getting the pricing that is tied to some of the investments that we're making for those EO enhancements, and that's on track.

Okay, and the last one quickly on the CapEx. I believe there were two green fields historically discussed. One is this x-ray facility that comes online in the third quarter. Maybe I'm stale on this, but I thought the second one you had kind of put on the shelf pending discussions with clients and commitments around that. And I wondered, I needed a reminder on the status on that second one.

Yeah, definitely, David. Your recollection is correct as usual. We had put that on a brief pause. It's called a brief pause. And that was some of the reason why our CapEx last year stepped down so meaningfully from our initial guide. and also part of the reason why our CapEx came back this year is because we're full go on that project, making really good progress with the team there and expect that to be finished up towards the end of next year, early 28.

Okay, thank you.

Thank you.

The next question is from Brett Fishman with KeyBank. Please go ahead.

Hey, this is Will on for Brett. I just wanted to circle back on the XPU activities. I think you commented on it a little bit earlier, but could you just directionally quantify how meaningful those opportunities and efforts are becoming and where do you see the greatest opportunity for additional penetration among those customers?

Yeah, so thanks for that. So I do believe it is a meaningful opportunity. We obviously add a lot of value with our Sterigenics business unit, but also a lot of value with Nelson Labs, and the two are absolutely complementary. So that high level, that's one point. We have had an effort to ensure that our teams are working well together and that we are providing solutions to our customers that are differentiated just based on the high level of expertise that we have within each of those businesses. We do look at this as a meaningful opportunity for growth as we get into the planning period here and also it does absolutely impact our customer satisfaction. So when our customers are working seamlessly between Soterra Health Business Units, they're happier. And that's one of our key goals as a service provider to delight our customers every single day.

Thank you. I appreciate the color on that. And then just one more. How is utilization as it stands today? Are there any particular geographies or modalities where you're seeing capacity becoming more constrained?

Yeah, we're in a good position to support our customers right now with capacity available most places. There are, as we've talked before, EO in the U.S. continues to be a place, particularly in large chambers, where there's a little tighter capacity in places where it's more difficult. As you know, this is a geographic business and modality-based business, and so having the right modality in the right location is critical for the customer. And so those are things we work through, but that's the only thing that I really call out.

All right, thank you very much, and again, welcome to the team, Alton. Thank you.

The next question is from Joseph Downing with Piper Sandler. Please go ahead.

Hey, good morning, and congrats on the quarter. Thanks for taking the question. Just wanted to follow up quick on Sterigenics pricing. So as you head into the 27 contract conversations, Is there anything that changes the ceiling on price here, whether that's customers, you know, potentially pushing back harder? It doesn't sound like that's an issue, but just wanted to confirm. And then are you anything with competitors getting more aggressive with to win volume or inflation, you know, boiling to the point where the passer argument might get a little tougher to make?

Yeah, thank you for the question. Appreciate that. So, again, I don't see today and or our team's not seeing today A material difference in competition. Again, the competition is always fierce in our market and that's just something that we work through and we deal with every day. For pricing, we take an approach that we price for the value that we provide to our customers. And again, our commercial team has done a very nice job with that historically and we expect them to continue to deliver on that in the future.

Great, appreciate that. And then just one on capital deployment here. So you're now inside your leverage target, about $950 million of liquidity, nothing drawn on the revolver. Just curious, what's the priority stack from here? Is it building more cushion? Is it M&A in a specific area? Or does it buy back maybe into the conversation here at these levels? Thanks.

Yeah, no, thank you. Really appreciate that question. We haven't had a chance to talk about that yet. This is obviously a really important time when it comes to capital allocation for our business. We are going to generate a significant amount of free cash flow over the course of the next few years. And as I look at our long-term growth and our long-term strategies, my primary goal is to be able to accelerate growth within this business. We've got to become more essential to our customers. We've got to become easier to work with. We've got to have best-in-class operations. and importantly, we've got to be able to effectively allocate our capital to maximize that growth. So we are heavily involved in that process right now. We're also kicking off our strategic planning process and working through some of our key strategic priorities and strategic initiatives. So I'm looking forward to sharing our priorities on capital allocation as we go forward. I'll note that where we are today with a focus on internal investment and M&A particularly focused around on the sterilization side and Nelson Labs, I'm aligned with that. But we are getting deep into that right now and I look forward to sharing more with you all once we have that more nailed down.

Thanks, Alton. Welcome to the team.

Yeah, thanks.

The next question is from Michael Polark with Wolf Research. Please go ahead.

Hey, good morning. Jumping around calls, so if you commented already on litigation, I apologize for this question, but can we get a brief litigation update? I see New Mexico, which was always one of the smaller items on EO, settled in early July, so I'm interested in just your comment on that. It seems like a small win. And then the next steps in Georgia, and California, what is on the calendar for later this year and what's still circled for 27.

Hey, Mike, it's Michael. Good morning. So I'll take the questions on the litigation side. So as far as Georgia, you know, we're going through the appellate process right now. Obviously, you know, our view is the court's rejection of the plaintiff's general causation theory is a critical issue. comment all the cases and we believe this underscores the lack of reliable scientific support so I would say that is an overarching statement we'd expect to hear something in spring summer on the appellate process you know we've got a team fully engaged and we feel very good about where we sit relatives those rulings have come out today the case and you mentioned New Mexico that was settled in July that model is not material to the company and settlements fully and finally resolve all the claims asserted or that could have been asserted in the lawsuit. So we're happy to have that behind you. We felt all along that that was not a legitimate claim and we've been very consistent in that and we're happy to be able to resolve that for an immaterial impact to the company. And then lastly, on the California litigation, we'll continue to work through the court hearings and procedures and processes and in different motions and rulings and everything else that comes along with this process at this point in time. We expect the trials to be in January of April of 2027 at this point in time. That always could change based on how things play out. I don't think it'll be any earlier than that. It could get pushed out slightly, but ultimately that'll be determined by the judge in this process.

Thank you, Michael. For the follow-up, I want to fish on the large customer that's coming on in the second half in Sterigenics. Is this across your global network? Is it specific to a modality or geography? And the mention of this customer used to insource and now is outsourcing, are they shutting down internal capacity or they just had growth needs and for those growth needs, they're coming to you, but they're still keeping some some level of service in-house. I'd welcome any color on this large customer. Thank you.

Hey, Mike, thanks for the question. Yeah, this is the one customer that we've been talking about. You can surmise this was an insource-outsource shift related to EO in North America when you think about what we've talked about historically. a meaningful customer that they're shutting down capacity and moving the business to us. So we're happy to support them and move this forward, but it's nothing new. This is the one we've been talking about for a while.

Thank you.

This concludes our question and answer session. I would like to turn the conference back over to Alton for closing remarks.

Thanks, Operator, and thank you all for joining us today. I continue to be really excited about Sotera's opportunities, and we as a team look forward to executing on the back half of the year, and I look forward to engaging with you all as we further develop our strategic priorities. So thanks again for joining. Hope you all have a good week. Take care. Thank you.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.